

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/939,769	939,769 08/28/2001 James P. Hoeffler	039322-0226	3866		
22428 7	590 04/29/2003				
FOLEY AND	LARDNER		EXAMI	NER	
SUITE 500 3000 K STREET NW WASHINGTON, DC 20007			RAWLINGS, STEPHEN L		
			ART UNIT	PAPER NUMBER	
			1642	11.	
			DATE MAILED: 04/29/2003	(9	

Please find below and/or attached an Office communication concerning this application or proceeding.

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
				EVAMINED
			<u></u>	EXAMINER
			ART UNIT	PAPER
				14
			DATE MAILED	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed 10 January 2002 is not fully responsive to the Office communication mailed 10 October 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules and reiterated herein. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Figure 2 recites, "DPKKKRKV" and "SEKDEL", amino acid sequences of sufficient length to require compliance with the sequence rules; however, while the brief description of the figure includes references to sequence identification numbers, it is not apparent which numbers correspond to which sequences. Additionally, on pages 4, 5, and 23, the specification recites "ITSP", which is also not properly identified by a sequence identification number corresponding to the same sequence set forth in the sequence listing. Applicant is required to make appropriate corrections to place this application in compliance with the rules and if necessary to do so, Applicants must submit substitute copies of the sequence listing and a statement that both copies are the same and include no new matter.

Since the reply appears to be <u>bona fide</u> attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Stephen L. Rawlings, Ph.D., Art Unit 1642, whose telephone number is (703) 305-3008.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

PRaulen STEPHEN RANLINGS

N	nti	2	to	Co	m	nl	\ /
	O CI	CC	U	00		PI	y

Application No.	Applicant(s)
09/939,769	HOEFFLER ET AL.
Examiner	Art Unit
Stephen L. Rawlings, Ph.D.	1642

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: This application contains sequences not properly identified by sequence identification numbers in Figure 2 and on pages 4, 5, and 23. Applicants should amend the specification to recite sequence identification numbers and if necessary, as indicated below, submit substitute copies of the sequence listing and the statement that both copies are the same and include no new matter.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY